Clinical trial
A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Lead sponsor
- Processa Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 2, 2024
- Completion date
- July 29, 2026
- Enrollment
- 20 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, her2-negative breast cancer, tnbc - triple-negative breast cancer